RayKnowChina Research Map
Shortlist

Zhejiang University School of Medicine

浙江大学医学院

HangzhouUniversity or health system

Hospitals that carry this university's name, added together, plus papers and trials that name only the university.

Research activity, not treatment quality. Not medical advice. How this works

Nasopharyngeal carcinoma

鼻咽癌
0.5%Leads under 1 in 100 of China's research papers on NPC

Led 12 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (23.4%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
1
Share of China's trials
0.2%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 332025
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseImaging & AI

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University5
  2. Sir Run Run Shaw Hospital4
  3. Stomatology Hospital1
  4. Second Affiliated Hospital, Zhejiang University1
  5. Zhejiang University Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Machine learning model for predicting recurrence following intensity-modulated radiation therapy in nasopharyngeal carcinoma.2025World journal of surgical oncologyFree full text
  2. Establishing a Risk Prediction Model for Nasopharyngeal Carcinoma Based on Anti-BNLF2b Serological Biomarkers: A Retrospective Study.2025International journal of medical sciencesFree full text
  3. The global burden of nasopharyngeal carcinoma from 2009 to 2019: an observational study based on the Global Burden of Disease Study 2019.2022European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck SurgeryFree full text
  4. An isodose-constrained automatic treatment planning strategy using a multicriteria predicted dose rating.2025Medical physicsFree full text
  5. A Preliminary Study on Transcriptional Regulation of SNP Site C-1888T in the Promoter Region of Human PLUNC Gene and Nasopharyngeal Carcinoma Susceptibility.2024Genetics researchFree full text
Trials on ClinicalTrials.gov3
  1. A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma PatientsStatus unknownNCT04061278Lead sponsorPhase 3Start 2019-08
  2. Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid TumorsCompletedNCT04215978Study sitePhase 1Start 2020-01
  3. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12

PubMed searchClinicalTrials.gov

Oesophageal squamous cell carcinoma

食管鳞状细胞癌
0.7%Leads under 1 in 100 of China's research papers on ESCC

Led 20 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.9%).

Run this PubMed search

Open trials led
3
Research papers it led
20
Trials it led
12
Share of China's trials
2.1%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesNeoadjuvant & combined treatmentImmunotherapySurgery

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University11
  2. Second Affiliated Hospital, Zhejiang University4
  3. Hangzhou Cancer Hospital2
  4. Taizhou Hospital Counted in the group total1
  5. Affiliated Jinhua Hospital of Zhejiang University1
  6. Sir Run Run Shaw Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Neoadjuvant Chemoimmunotherapy for Elderly Patients with Locally Advanced Resectable Esophageal Squamous Cell Carcinoma.2026Annals of surgical oncology
  2. Neoadjuvant serplulimab combined with chemotherapy for resectable oesophageal squamous cell carcinoma: a single-arm, phase 2 trial.2025Nature communicationsFree full text
  3. Neoadjuvant chemoimmunotherapy cycles in locally advanced Esophageal squamous cell carcinoma: a retrospective comparison of three versus two cycles.2025Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  4. Long-term outcomes after Ivor-Lewis versus McKeown esophagectomy with two-field lymphadenectomy for resectable middle or lower thoracic esophageal squamous cell carcinoma.2025Langenbeck's archives of surgeryFree full text
  5. Tumor deposits in the impact of esophageal squamous cell carcinoma prognosis and recurrence: A multicenter retrospective cohort study.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Trials on ClinicalTrials.gov6
  1. Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07505186Lead sponsorPhase 2Start 2026-08
  2. Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT07244978Lead sponsorPhase 2Start 2026-06
  3. Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingNCT06576973Lead sponsorPhase 2Start 2024-08
  4. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  5. Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCCRecruitingNCT05507411Study sitePhase 2Start 2022-08
  6. A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT07142421Lead sponsorPhase 2Start 2025-08

PubMed searchClinicalTrials.gov

Hepatocellular carcinoma

肝细胞癌
3.5%Leads about 1 in 28 of China's research papers on HCC

Led 520 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (5.5%).

Run this PubMed search

Open trials led
21
Research papers it led
520
Trials it led
70
Share of China's trials
4.8%
Share of the world's papers
1.8%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 332025
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University254
  2. Sir Run Run Shaw Hospital83
  3. Second Affiliated Hospital, Zhejiang University68
  4. Fourth Affiliated Hospital, Zhejiang University11
  5. Affiliated Jinhua Hospital of Zhejiang University8
  6. Fourth Affiliated Hospital of Zhejiang University6

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.2022Journal for immunotherapy of cancerRCTFree full text
  2. Adjuvant transarterial chemoembolization for hepatocellular carcinoma following curative resection: A randomized, open-label, phase 3 trial.2025Hepatology (Baltimore, Md.)RCT
  3. The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial.2023Hepatobiliary & pancreatic diseases international : HBPD INTRCT
  4. Sex Differences in Risk of Adverse Liver Events in Patients With Cirrhosis.2025JAMA network openFree full text
  5. Oncolytic virus VG161 in refractory hepatocellular carcinoma.2025Nature
Trials on ClinicalTrials.gov6
  1. Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCCNot yet recruitingNCT07596134Lead sponsorN/AStart 2026-10
  2. Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic CholangiocarcinomaNot yet recruitingNCT07328802Lead sponsorPhase 2Start 2026-01
  3. A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCRecruitingNCT07422753Lead sponsorPhase 2Start 2026-03
  4. Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular CarcinomaNot yet recruitingNCT07487402Lead sponsorEarly phase 1Start 2026-03
  5. A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical ResectionRecruitingNCT07495215Lead sponsorPhase 1/Phase 2Start 2025-09
  6. Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular CarcinomaRecruitingNCT07123545Lead sponsorPhase 1/Phase 2Start 2025-08

PubMed searchClinicalTrials.gov

Stomach cancer

胃癌
2.1%Leads about 1 in 48 of China's research papers on Stomach cancer

Led 203 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (3.9%).

Run this PubMed search

Open trials led
21
Research papers it led
203
Trials it led
44
Share of China's trials
3.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 442025
ThemesPeritoneal spread & advanced diseaseImaging & AIImmunotherapy & targeted drugs

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University63
  2. Second Affiliated Hospital, Zhejiang University58
  3. Sir Run Run Shaw Hospital44
  4. Affiliated Jinhua Hospital of Zhejiang University6
  5. Children's Hospital, Zhejiang University School of Medicine Counted in the group total4
  6. Fourth Affiliated Hospital of Zhejiang University Counted in the group total4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.2022JAMA network openRCTFree full text
  2. Early Oral Feeding is Safe and Comfortable in Patients with Gastric Cancer Undergoing Radical Total Gastrectomy.2025Nutrition and cancerRCT
  3. High Loss of Adipose Tissue During Neoadjuvant Chemotherapy Predicts Poor Prognosis in Patients With Gastric Cancer.2025Journal of cachexia, sarcopenia and muscleRCTFree full text
  4. The immune signatures predict gastric/gastroesophageal junction cancer response to first-line anti-PD-1 blockade or chemotherapy.2025BMC cancerRCTFree full text
  5. Application of Problem-Oriented Nursing Model Combined with Early Enteral Nutrition Support in the Perioperative Period of Stage II/III Gastric Cancer Patients.2025Nutrition and cancerRCT
Trials on ClinicalTrials.gov6
  1. Tafolecimab Combined With Sintilimab and SOX in the Treatment of pMMR/MSS Gastric CancerNot yet recruitingNCT07621562Lead sponsorPhase 2Start 2026-06
  2. AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric CancerRecruitingNCT07525765Lead sponsorStart 2026-04
  3. 18F-FAPI PET/CT and MRI in Gastric CancerNot yet recruitingNCT07510867Lead sponsorStart 2026-05
  4. AI-Assisted Novel rbcDNA Detection for Early Gastric Cancer DiagnosisNot yet recruitingNCT07782294Lead sponsorStart 2026-09
  5. High-Flow Nasal Cannula Oxygenation During Sedated Gastrointestinal Endoscopy in Patients With Chronic Obstructive Pulmonary DiseaseNot yet recruitingNCT07791979Lead sponsorN/AStart 2026-08
  6. COMBO Endoscopy Oropharyngeal Airway Reduces Hypoxia During Sedated Gastrointestinal Endoscopy in Obese Patients: A Multicenter, Randomized, Controlled Clinical TrialRecruitingNCT06796764Lead sponsorN/AStart 2025-04

PubMed searchClinicalTrials.gov

Retinoblastoma

视网膜母细胞瘤
0.7%Leads under 1 in 100 of China's research papers on Retinoblastoma

Led 2 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University1
  2. First Affiliated Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Osteosarcoma

骨肉瘤
2.0%Leads about 1 in 50 of China's research papers on Osteosarcoma ▼ from 2.9%

Led 45 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
45
Trials it led
5
Share of China's trials
8.6%
Share of the world's papers
0.9%
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 0020242025: 112025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University16
  2. Sir Run Run Shaw Hospital10
  3. First Affiliated Hospital, Zhejiang University8
  4. Children's Hospital, Zhejiang University School of Medicine5
  5. Fourth Affiliated Hospital, Zhejiang University2
  6. Affiliated Jinhua Hospital of Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gastrointestinal stromal tumour

胃肠道间质瘤
3.2%Leads about 1 in 31 of China's research papers on Gastrointestinal stromal tumour ▼ from 4.4%

Led 17 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.3%).

Run this PubMed search

Open trials led
1
Research papers it led
17
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 3320242025: 112025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University9
  2. Second Affiliated Hospital, Zhejiang University4
  3. Sir Run Run Shaw Hospital2
  4. Affiliated Jinhua Hospital of Zhejiang University1
  5. Second Affiliated Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Neuroblastoma

神经母细胞瘤
1.4%Leads about 1 in 71 of China's research papers on Neuroblastoma

Led 16 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.8%).

Run this PubMed search

Open trials led
1
Research papers it led
16
Trials it led
2
Share of China's trials
4.8%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

PubMed searchClinicalTrials.gov

Multiple myeloma

多发性骨髓瘤
3.9%Leads about 1 in 25 of China's research papers on Myeloma

Led 66 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.8%).

Run this PubMed search

Open trials led
8
Research papers it led
66
Trials it led
17
Share of China's trials
3.5%
Share of the world's papers
0.7%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025
ThemesRelapse & resistanceCAR-T & cell therapyDrug combinations

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University55
  2. Second Affiliated Hospital, Zhejiang University5
  3. Sir Run Run Shaw Hospital4
  4. Fourth Affiliated Hospital of Zhejiang University Counted in the group total1
  5. Affiliated Jinhua Hospital of Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma.2025Journal for immunotherapy of cancerFree full text
  2. Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy.2026Bone marrow transplantation
  3. Sequential intrathoracic injection and intravenous infusion of BCMA CAR-T cells in a patient with relapsed/refractory primary plasma cell leukemia.2025International journal of hematology
  4. Determining the factors affecting bortezomib's adverse events in the treatment of newly diagnosed multiple myeloma.2025Hematology (Amsterdam, Netherlands)
  5. Serum ferritin can serve as a biomarker for the prognosis and increased the prognostic predictive value of ISS/RISS in multiple myeloma patients.2025Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
Trials on ClinicalTrials.gov6
  1. Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT07359014Lead sponsorN/AStart 2025-11
  2. A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT06644118Lead sponsorPhase 1Start 2024-10
  3. Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or NotRecruitingNCT06463717Lead sponsorStart 2023-12
  4. APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple MyelomaRecruitingNCT04657861Lead sponsorEarly phase 1Start 2022-05
  5. Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple MyelomaRecruitingNCT05722405Lead sponsorPhase 4Start 2022-07
  6. CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic DiseasesRecruitingNCT04662294Lead sponsorEarly phase 1Start 2021-11

PubMed searchClinicalTrials.gov

B-cell acute lymphoblastic leukaemia (B-ALL)

B 细胞急性淋巴细胞白血病
4.4%Leads about 1 in 23 of China's research papers on B-ALL ▲ from 2.0%

Led 10 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.9%).

Run this PubMed search

Open trials led
13
Research papers it led
10
Trials it led
27
Share of China's trials
10.7%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 332025
ThemesPhiladelphia chromosome & geneticsChildrenCAR-T & cell therapy

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University5
  2. Children's Hospital, Zhejiang University School of Medicine5

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Integrated prognostic value of MRD and cytogenetics in adolescent and adult B-cell acute lymphoblastic leukaemia.2026British journal of haematology
  2. Allogeneic Hematopoietic Stem Cell Transplantation Abrogates the Poor Prognosis of High-Risk Cytogenetics in Adult Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia.2026Clinical lymphoma, myeloma & leukemia
  3. The impact of asparaginase phenotype-related single nucleotide polymorphisms on prognosis in pediatric B-cell precursor acute lymphoblastic leukemia.2025European journal of medical researchFree full text
  4. Safety and efficacy of CD19-targeted CAR-T-cell therapy for patients with relapsed or refractory TCF3-PBX1 fusion gene-positive B-ALL.2025Hematology (Amsterdam, Netherlands)
  5. Leukemia Burden Impacts the Efficacy and Toxicity of Blinatumomab in Pediatric B-Cell Acute Lymphoblastic Leukemia.2025Cancer medicineFree full text
Trials on ClinicalTrials.gov6
  1. KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic LeukemiaRecruitingNCT07246707Lead sponsorPhase 1Start 2026-01
  2. Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic LeukemiaRecruitingNCT07429461Lead sponsorEarly phase 1Start 2026-02
  3. Effectiveness and Safety of InO±DLI for Relapsed B-ALL/LBL After Allo-HSCTNot yet recruitingNCT06861348Lead sponsorPhase 2Start 2025-03
  4. JY231(JY231) Injection for the Treatment of Relapsed or Refractory B-Cell LeukemiaNot yet recruitingNCT06902025Lead sponsorN/AStart 2025-03
  5. Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT07003737Lead sponsorN/AStart 2025-02
  6. Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic LeukemiaRecruitingNCT06793241Lead sponsorEarly phase 1Start 2025-01

PubMed searchClinicalTrials.gov

Aplastic anaemia

再生障碍性贫血
1.5%Leads about 1 in 68 of China's research papers on Aplastic anaemia ▼ from 2.1%

Led 6 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
1
Research papers it led
6
Trials it led
1
Share of China's trials
1.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 2220232024: 1120242025: 112025
ThemesChildrenImmunosuppressive treatmentThrombopoietin drugs

Hospitals counted here

  1. Children's Hospital, Zhejiang University School of Medicine2
  2. Second Affiliated Hospital, Zhejiang University Counted in the group total1
  3. Affiliated Jinhua Hospital of Zhejiang University1
  4. Children's Hospital, Medical College of Zhejiang University1
  5. First Affiliated Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增生症
6.5%Leads about 1 in 15 of China's research papers on HLH

Led 26 of 399 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.3%).

Run this PubMed search

Open trials led
0
Research papers it led
26
Trials it led
1
Share of China's trials
2.1%
Share of the world's papers
1.6%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 442025
ThemesDiagnosis & prognosisTreatment regimensChildren

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University14
  2. Children's Hospital, Zhejiang University School of Medicine8
  3. Second Affiliated Hospital, Zhejiang University2
  4. Affiliated Jinhua Hospital of Zhejiang University1
  5. Sir Run Run Shaw Hospital Counted in the group total1
  6. Medicine First Affiliated Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Haemophilia A

血友病 A
1.5%Leads about 1 in 68 of China's research papers on Haemophilia A

Led 4 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (15.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.1%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led4
  1. From pharmacokinetic-guided FVIII prophylaxis to low-dose Emicizumab prophylaxis: a pilot study revealed a flush of hope.2025Annals of hematology
  2. Transforming hemophilia care: emerging therapeutic innovations and challenges.2025Expert review of hematology
  3. The Need for a Bleed Type-Specific Annual Bleeding Rate in Hemophilia Studies.2024JMIR public health and surveillance
  4. Letter to the Editor Regarding "Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China".2024Advances in therapy
Trials on ClinicalTrials.gov6
  1. Study of Efficacy and Safety of FRSW107 in Pediatric Patients With Severe Hemophilia ANot yet recruitingNCT06136507Study sitePhase 3Start 2026-12
  2. Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCompletedNCT06738485Study sitePhase 3Start 2025-01
  3. A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia AActive, not recruitingNCT05685238Study sitePhase 3Start 2023-02
  4. Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion ProteinCompletedNCT06142552Study sitePhase 3Start 2023-12
  5. A Research Study Looking at Mim8 in Children With Haemophilia A With or Without InhibitorsCompletedNCT05306418Study sitePhase 3Start 2022-04
  6. A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without InhibitorsCompletedNCT05053139Study sitePhase 3Start 2021-12

PubMed searchClinicalTrials.gov

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜
6.2%Leads about 1 in 16 of China's research papers on Thrombotic thrombocytopenic purpura ▼ from 8.7%

Led 4 of 64 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 1120242025: 112025

PubMed searchClinicalTrials.gov

Neuromyelitis optica spectrum disorder (NMOSD)

视神经脊髓炎谱系疾病
2.1%Leads about 1 in 49 of China's research papers on NMOSD

Led 10 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.5%).

Run this PubMed search

Open trials led
0
Research papers it led
10
Trials it led
1
Share of China's trials
1.3%
Share of the world's papers
0.5%
Papers led per year
2021: 2220212022: 2220222023: 0020232024: 1120242025: 002025
ThemesAntibodies & diagnosisOptic nerve & visionImaging

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University7
  2. First Affiliated Hospital, Zhejiang University3

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgG4-related disease

IgG4相关性疾病
2.4%Leads about 1 in 41 of China's research papers on IgG4-RD

Led 6 of 246 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.1%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 3320242025: 002025
ThemesDiagnosis & look-alikesLung & chestKidney, retroperitoneum & vessels

Hospitals counted here

  1. Sir Run Run Shaw Hospital3
  2. First Affiliated Hospital, Zhejiang University2
  3. Second Affiliated Hospital, Zhejiang University Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Myasthenia gravis

重症肌无力
1.0%Leads about 1 in 100 of China's research papers on Myasthenia gravis ▲ from 0.4%

Led 5 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.6%).

Run this PubMed search

Open trials led
2
Research papers it led
5
Trials it led
4
Share of China's trials
4.3%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 112025
ThemesThymus & thymectomyAntibodies & diagnosisPregnancy, children, older adults

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University4
  2. Children's Hospital, Zhejiang University School of Medicine1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Erythroderma in a Patient With Thymoma-Associated Myasthenia Gravis.2024JAMA dermatology
  2. Normotensive primary aldosteronism in a patient with myasthenia gravis: a localization diagnostic conundrum unraveled by 68Ga-pentixafor PET/CT - a case report with review of literature.2025Endocrine
  3. Dynamic changes of peripheral inflammatory markers link with disease severity and predict short-term poor outcome of myasthenia gravis.2024Journal of neurochemistry
  4. Small extracellular vesicle microRNAs in pediatric myasthenia gravis plasma and skeletal muscle.2024Postgraduate medical journal
  5. Contrast-enhanced CT-based radiomics differentiate anterior mediastinum lymphoma from thymoma without myasthenia gravis and calcification.2024Clinical radiology
Trials on ClinicalTrials.gov6
  1. A Study on the Efficacy and Safety of Telitacicept in the Treatment of Children Ocular Myasthenia GravisNot yet recruitingNCT07298928Lead sponsorN/AStart 2026-03
  2. UCAR T-cell Therapy Targeting CD19/BCMA in Patients With r/r Myasthenia GravisNot yet recruitingNCT06933563Lead sponsorEarly phase 1Start 2025-04
  3. A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.RecruitingNCT06447597Study sitePhase 2/Phase 3Start 2024-07
  4. A Study of Nipocalimab Administered to Adults With Generalized Myasthenia GravisRecruitingNCT04951622Study sitePhase 3Start 2021-07
  5. An Exploratory Clinical Study of GC012F Injection for Refractory gMGWithdrawnNCT06419166Lead sponsorEarly phase 1Start 2024-12
  6. Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia GravisStatus unknownNCT05828225Lead sponsorPhase 1Start 2023-04

PubMed searchClinicalTrials.gov

Moyamoya disease

烟雾病
3.4%Leads about 1 in 30 of China's research papers on Moyamoya ▲ from 2.2%

Led 12 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (19.9%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.0%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 4420242025: 002025
ThemesImaging & blood flowRevascularisation surgeryChildren

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University12

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Wilson disease

肝豆状核变性(Wilson 病)
6.5%Leads about 1 in 15 of China's research papers on Wilson disease ▼ from 8.3%

Led 13 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.5%).

Run this PubMed search

Open trials led
3
Research papers it led
13
Trials it led
5
Share of China's trials
31.2%
Share of the world's papers
1.9%
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 0020242025: 112025
ThemesGenetics (ATP7B)Diagnosis & copper testsTreatment (chelation, zinc)

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University8
  2. First Affiliated Hospital, Zhejiang University4
  3. Sir Run Run Shaw Hospital Counted in the group total1
  4. Children's Hospital, Zhejiang University School of Medicine Counted in the group total1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Age and Serum Creatinine Can Differentiate Wilson Disease Patients with Pseudonormal Ceruloplasmin.2023International journal of clinical practiceFree full text
  2. Serum Neurofilament Light Chain in Wilson's Disease: A Promising Indicator but Unparallel to Real-Time Treatment Response.2022Movement disorders : official journal of the Movement Disorder Society
  3. Emerging neurological symptoms after liver transplantation: A 6-year follow-up of an adolescent patient with Wilson's disease.2022CNS neuroscience & therapeuticsFree full text
  4. Prevalent Pathogenic Variants of ATP7B in Chinese Patients with Wilson's Disease: Geographical Distribution and Founder Effect.2021GenesFree full text
  5. Neuroimaging correlates of genetics in patients with Wilson's disease.2025Cerebral cortex (New York, N.Y. : 1991)
Trials on ClinicalTrials.gov6
  1. A Clinical Study to Evaluate the Safety and Efficacy of LY-M003 Injection in Patients With Wilson DiseaseRecruitingNCT06650319Lead sponsorEarly phase 1Start 2024-09
  2. Clinical Features and Outcome in Patients With Osseomuscular Type of Wilson's DiseaseRecruitingNCT04965558Lead sponsorStart 2004-01
  3. Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson DiseaseRecruitingNCT04965545Lead sponsorStart 2004-01
  4. Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.RecruitingNCT07465718Study sitePhase 3Start 2026-09
  5. Phase I/II Clinical Study to Evaluate the Safety, Tolerability and Efficacy of LY-M003 Injection in Adult Patients With Wilson's DiseaseNot yet recruitingNCT07641140Study sitePhase 1/Phase 2Start 2026-06
  6. The Individual Therapy for Patients With Wilson's DiseaseStatus unknownNCT03957720Lead sponsorEarly phase 1Start 2019-03

PubMed searchClinicalTrials.gov

Biliary atresia

胆道闭锁
1.9%Leads about 1 in 53 of China's research papers on Biliary atresia

Led 4 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.8%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
1
Share of China's trials
5.0%
Share of the world's papers
0.5%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 222025
ThemesScreening & diagnosisDisease mechanismsLiver transplant

Hospitals counted here

  1. Children's Hospital, Zhejiang University School of Medicine2
  2. First Affiliated Hospital, Zhejiang University2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎
3.0%Leads about 1 in 33 of China's research papers on Anti-NMDA receptor encephalitis ▲ from 2.4%

Led 8 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
8
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
1.1%
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 2220242025: 112025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University4
  2. Second Affiliated Hospital, Zhejiang University4
  3. Affiliated Zhejiang Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Takayasu arteritis

大动脉炎
1.1%Leads about 1 in 93 of China's research papers on Takayasu arteritis New since 2021

Led 2 of 187 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (24.6%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
4.0%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University1
  2. Sir Run Run Shaw Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Idiopathic pulmonary fibrosis

特发性肺纤维化
1.2%Leads about 1 in 83 of China's research papers on Idiopathic pulmonary fibrosis ▲ from 0.7%

Led 12 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (4.3%).

Run this PubMed search

Open trials led
0
Research papers it led
12
Trials it led
1
Share of China's trials
1.4%
Share of the world's papers
0.3%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University4
  2. First Affiliated Hospital, Zhejiang University4
  3. Affiliated Jinhua Hospital of Zhejiang University1
  4. Affiliated Huzhou Hospital of Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Genome editing of Spp1 by inhalable CRISPR/Cas9 formulation for treating pulmonary fibrosis.2026Journal of controlled release : official journal of the Controlled Release Society
  2. Identification of key genes associated with idiopathic pulmonary fibrosis and sarcopenia by bioinformatics analysis.2025PloS one
  3. An Overview of the Role of Genetic factors in Idiopathic Pulmonary Fibrosis: Insights from Epidemiology to Prognosis.2025International journal of medical sciences
  4. Identification of DNA damage repair-related diagnostic markers for idiopathic pulmonary fibrosis via WGCNA.2025Computational biology and chemistry
  5. PINK1 deficiency alleviates bleomycin-induced pulmonary fibrosis in mice.2025Cellular signalling
Trials on ClinicalTrials.gov6
  1. Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT07687459Study sitePhase 3Start 2026-09
  2. Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective StudyNot yet recruitingNCT06922916Lead sponsorStart 2025-04
  3. Treatment of Idiopathic Pulmonary Fibrosis (IPF) by REGEND007 Cell TherapyNot yet recruitingNCT07359963Study siteEarly phase 1Start 2026-02
  4. A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastActive, not recruitingNCT06238622Study sitePhase 3Start 2024-09
  5. A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT06335303Study sitePhase 2Start 2024-09
  6. Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT05938920Study sitePhase 2Start 2023-06

PubMed searchClinicalTrials.gov

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病
4.4%Leads about 1 in 23 of China's research papers on Lymphangioleiomyomatosis New since 2021

Led 2 of 45 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (31.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Sir Run Run Shaw Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症
1.8%Leads about 1 in 56 of China's research papers on Amyotrophic lateral sclerosis ▲ from 1.0%

Led 14 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (8.3%).

Run this PubMed search

Open trials led
0
Research papers it led
14
Trials it led
1
Share of China's trials
1.8%
Share of the world's papers
0.2%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 222025

Over half of these papers are lab or animal studies.

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University6
  2. First Affiliated Hospital, Zhejiang University5
  3. Children's Hospital, Zhejiang University School of Medicine1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

Papers it led5
  1. Taste loss as the sole presenting symptom in Chinese patient with facial onset sensory and motor neuronopathy.2021CNS neuroscience & therapeutics
  2. Deciphering the Inhibitory Mechanism of ALS-Associated N352S and S352p Variants against TDP-43 Aggregation and Its Destabilization Effect on TDP-43 Protofibrils.2025ACS chemical neuroscience
  3. Novel subcellular regulatory mechanisms of protein homeostasis and its implications in amyotrophic lateral sclerosis.2025Biochemical and biophysical research communications
  4. Clinical characterization and founder effect analysis in Chinese amyotrophic lateral sclerosis patients with SOD1 common variants.2024Annals of medicine
  5. FUS reads histone H3K36me3 to regulate alternative polyadenylation.2024Nucleic acids research
Trials on ClinicalTrials.gov4
  1. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene MutationRecruitingNCT06556394Study sitePhase 1Start 2024-12
  2. Explore Neuroprotective Effect of Lipoic Acid in Amyotrophic Lateral SclerosisStatus unknownNCT04518540Lead sponsorN/AStart 2020-09
  3. A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALSNot yet recruitingNCT07169175Study sitePhase 1/Phase 2Start 2025-12
  4. An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral SclerosisNot yet recruitingNCT06645197Study siteEarly phase 1Start 2024-10

PubMed searchClinicalTrials.gov

Spinal muscular atrophy

脊髓性肌萎缩症
3.6%Leads about 1 in 27 of China's research papers on Spinal muscular atrophy New since 2021

Led 2 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (29.1%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
1
Share of China's trials
3.3%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 222025

Hospitals counted here

  1. Children's Hospital, Zhejiang University School of Medicine2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Fabry disease

法布雷病
5.5%Leads about 1 in 18 of China's research papers on Fabry disease New since 2021

Led 4 of 73 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.3%).

Run this PubMed search

Open trials led
1
Research papers it led
4
Trials it led
1
Share of China's trials
7.1%
Share of the world's papers
0.5%
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 1120242025: 112025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University2
  2. Children's Hospital, Zhejiang University School of Medicine2

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Duchenne muscular dystrophy

杜氏肌营养不良
0.5%Leads under 1 in 100 of China's research papers on Duchenne muscular dystrophy ▼ from 7.1%

Led 1 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.8%).

Run this PubMed search

Open trials led
0
Research papers it led
1
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.04%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Behçet disease

白塞病
1.2%Leads about 1 in 82 of China's research papers on Behçet disease

Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (22.9%).

Run this PubMed search

Open trials led
0
Research papers it led
3
Trials it led
1
Share of China's trials
5.9%
Share of the world's papers
0.2%
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 112025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University2
  2. Sir Run Run Shaw Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Alport syndrome

Alport 综合征
3.5%Leads about 1 in 29 of China's research papers on Alport syndrome

Led 2 of 58 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (17.2%).

Run this PubMed search

Open trials led
0
Research papers it led
2
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.6%
Papers led per year
2021: 2220212022: 0020222023: 0020232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

IgA nephropathy

IgA 肾病
2.2%Leads about 1 in 46 of China's research papers on IgA nephropathy ▲ from 1.3%

Led 16 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (9.4%).

Run this PubMed search

Open trials led
4
Research papers it led
16
Trials it led
7
Share of China's trials
5.9%
Share of the world's papers
0.9%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 442025

Hospitals counted here

  1. Children's Hospital, Zhejiang University School of Medicine7
  2. Sir Run Run Shaw Hospital3
  3. First Affiliated Hospital, Zhejiang University2
  4. Second Affiliated Hospital, Zhejiang University2
  5. Fourth Affiliated Hospital, Zhejiang University1
  6. Fourth Affiliated Hospital of Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Gaucher disease

戈谢病
0.0%Leads none of China's research papers on Gaucher disease

Led 0 of 30 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (6.7%).

Run this PubMed search

Open trials led
1
Research papers it led
0
Trials it led
1
Share of China's trials
8.3%
Share of the world's papers
0.0%

PubMed searchClinicalTrials.gov

Primary biliary cholangitis

原发性胆汁性胆管炎
2.3%Leads about 1 in 43 of China's research papers on Primary biliary cholangitis ▼ from 4.0%

Led 7 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (12.0%).

Run this PubMed search

Open trials led
0
Research papers it led
7
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.7%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 3320242025: 112025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University4
  2. Sir Run Run Shaw Hospital1
  3. Affiliated Hangzhou Xixi Hospital of Zhejiang University1
  4. Affiliated Hangzhou Xixi Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Primary sclerosing cholangitis

原发性硬化性胆管炎
4.0%Leads about 1 in 25 of China's research papers on Primary sclerosing cholangitis ▲ from 2.0%

Led 4 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (7.0%).

Run this PubMed search

Open trials led
0
Research papers it led
4
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. First Affiliated Hospital, Zhejiang University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Congenital diaphragmatic hernia

先天性膈疝
8.3%Leads about 1 in 12 of China's research papers on Congenital diaphragmatic hernia

Led 5 of 60 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (18.3%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.4%
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 0020242025: 112025

Hospitals counted here

  1. Fourth Affiliated Hospital, Zhejiang University1
  2. Women's Hospital1
  3. Second Affiliated Hospital, Zhejiang University1
  4. Taizhou Hospital1
  5. Lishui Hospital, Zhejiang University1
  6. Jinhua Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Hirschsprung disease

先天性巨结肠
3.7%Leads about 1 in 27 of China's research papers on Hirschsprung disease ▲ from 0.7%

Led 6 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (13.0%).

Run this PubMed search

Open trials led
0
Research papers it led
6
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 0020212022: 0020222023: 2220232024: 1120242025: 222025

Hospitals counted here

  1. Children's Hospital, Zhejiang University School of Medicine4
  2. First Affiliated Hospital, Zhejiang University1
  3. Second Affiliated Hospital, Zhejiang University1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Familial adenomatous polyposis

家族性腺瘤性息肉病
8.5%Leads about 1 in 12 of China's research papers on Familial adenomatous polyposis ▲ from 3.9%

Led 5 of 59 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (10.2%).

Run this PubMed search

Open trials led
0
Research papers it led
5
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
0.8%
Papers led per year
2021: 3320212022: 0020222023: 2220232024: 0020242025: 002025

Hospitals counted here

  1. Second Affiliated Hospital, Zhejiang University4

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov

Leber hereditary optic neuropathy

Leber 遗传性视神经病变
21.1%Leads about 1 in 5 of China's research papers on Leber hereditary optic neuropathy

Led 11 of 52 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).

The bar compares it with the institution that has the largest share (21.1%).

Run this PubMed search

Open trials led
0
Research papers it led
11
Trials it led
0
Share of China's trials
0.0%
Share of the world's papers
3.5%
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 222025

Hospitals counted here

  1. Fourth Affiliated Hospital of Zhejiang University4
  2. Children's Hospital, Zhejiang University School of Medicine4
  3. Fourth Affiliated Hospital, Zhejiang University1
  4. Women's Hospital1

Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.

PubMed searchClinicalTrials.gov